Following specialists treat Ovarian Cancer. Help us improve our data based on your experience.
Specialty scores for Ovarian Cancer
Source: In partnership with Genetic and Rare Diseases Information Center, funded by the National Center for Advancing Translational Sciences, and the National Human Genome Research Institute https://rarediseases.info.nih.gov/gard.
Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).
Date Modified: 2015-03-30T13:39:00
Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Some people with ovarian cancer may experience the following:
Date Modified: 2015-03-27T15:02:00
Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition. They are due to random changes (mutations) that occur only in the cells of the ovary. These mutations (called somatic mutations) accumulate during a person's lifetime and are not inherited or passed on to future generations.
However, approximately 10-25% of ovarian cancers are thought to be "hereditary." These cases are caused by an inherited predisposition to ovarian cancer that is passed down through a family. In some of these families, the underlying genetic cause is not known. However, many of these cases are part of a hereditary cancer syndrome. For example, the following cancer syndromes are associated with an elevated risk of ovarian cancer and several other types of cancer:
Date Modified: 2015-03-27T15:45:00
Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition. However, approximately 10-25% of ovarian cancer is thought to be inherited. In some of these families, the underlying genetic cause is not known. However, many of these cases are part of a hereditary cancer syndrome such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome, which are inherited in an autosomal dominant manner. This means that a person only needs a change (mutation) in one copy of the responsible gene in each cell to have a hereditary predisposition to ovarian cancer and other cancers associated with these syndromes. In some cases, an affected person inherits the mutation from an affected parent. Other cases may result from new (de novo) mutations in the gene. A person with one of these syndromes has a 50% chance with each pregnancy of passing along the altered gene to his or her child.
Date Modified: 2015-03-29T15:34:00
If ovarian cancer is suspected based on the presence of certain signs and symptoms, the following tests and procedures may be recommended:
Date Modified: 2015-03-30T10:56:00
Unfortunately, research suggests that there are no benefits of ovarian cancer screening (using a CA-125 blood test and transvaginal ultrasound), even in women who are at an elevated risk due to their personal and/or family histories. Women who are at a high-risk for ovarian cancer may, therefore, want to discuss other preventative measures, such as prophylactic surgery, with their healthcare provider. In women with a known hereditary cancer syndrome, management should also include screening for the other component cancers. Please click on the following links for more information regarding the treatment and management of each condition:
Date Modified: 2015-03-29T15:58:00
The long-term outlook (prognosis) for women with ovarian cancer depends on many factors including the subtype of cancer and the stage at which the cancer is diagnosed. In general, epithelial ovarian cancers (the most common subtype) are often associated with a worse prognosis than more rare subtypes such as germ cell and stromal ovarian tumors.
Because early stages of ovarian cancer are often not associated with any specific signs or symptoms, many cases are, unfortunately, diagnosed at a later and less treatable stage. Late stage ovarian cancers are generally associated with a poor prognosis. For example, 5-year survival rates for women diagnosed with stage I ovarian cancer range from 79-87%, while the 5-year survival rates for women diagnosed with stage IV ovarian cancer are approximately 11%.
Date Modified: 2015-03-29T16:33:00
Abnormality of metabolism/homeostasis
Autosomal dominant inheritance
Ovarian papillary adenocarcinoma
Trade Name: DoxilÂ®
Indication: Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months
Trade Name: EthyolÂ®
Indication: To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
Trade Name: HexalenÂ®
Indication: Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.
Trade Name: Lynparza
Indication: Use of as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
Trade Name: Oncoscint CR/OV
Indication: For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.